166 High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with outcome on immune checkpoint inhibitors

• Razelle Kurzrock,
• Sarabjot Pabla,
• Shumei Kato,
• Nithya Krishnamurthy,
• Paul DePietro,
• Mary K Nesline,
• Jeffrey M Conroy,
• Daisuke Nishizaki,
• Scott M Lippman,
• Hirotaka Miyashita

Affiliations

Razelle Kurzrock

Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Sarabjot Pabla

1OmniSeq, Buffalo, NY, USA

Shumei Kato

2University of California, San Diego, San Diego, CA, USA

Nithya Krishnamurthy

1Icahn School of Medicine at Mount Sinai, New York, NY, USA

Paul DePietro

1OmniSeq, Buffalo, NY, USA

Mary K Nesline

OmniSeq, Inc, Buffalo, New York, USA

Jeffrey M Conroy

OmniSeq Inc, Buffalo, New York, USA

Daisuke Nishizaki

2Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA

Scott M Lippman

2Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA

Hirotaka Miyashita

3Dartmouth Cancer Center, Lebanon, NH, USA